KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Accured Expenses (2016 - 2025)

TherapeuticsMD's Change in Accured Expenses history spans 16 years, with the latest figure at -$237000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 65.7% year-over-year to -$237000.0; the TTM value through Dec 2025 reached $272000.0, up 127.04%, while the annual FY2025 figure was $272000.0, 127.04% up from the prior year.
  • Change in Accured Expenses reached -$237000.0 in Q4 2025 per TXMD's latest filing, down from $425000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $19.1 million in Q3 2022 to a low of -$14.1 million in Q4 2022.
  • Average Change in Accured Expenses over 5 years is -$377300.0, with a median of -$213500.0 recorded in 2025.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 3282.27% in 2022, then tumbled 331.82% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$8.9 million in 2021, then tumbled by 58.77% to -$14.1 million in 2022, then soared by 73.04% to -$3.8 million in 2023, then soared by 81.79% to -$691000.0 in 2024, then skyrocketed by 65.7% to -$237000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Change in Accured Expenses are -$237000.0 (Q4 2025), $425000.0 (Q3 2025), and -$190000.0 (Q2 2025).